Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Related MRK
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's ... (GuruFocus)
Related GE
GE Introduces Startup Current to Transform Energy Sector - New Co. Integrates GE's LED, Solar, Energy Storage & Electric Vehicle Businesses
Bill Ackman: I'd Support Mike Bloomberg For President, GE Isn't Cheap Enough And 'Lots Of New Stuff' On Herbalife
GE: Why We're Bullish On Its Long-Term Prospects (Seeking Alpha)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News


Related Articles (GE + MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters